Form 4 Filing for OnKure Therapeutics, Inc.

This filing details a transaction by Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc. On December 22, 2025, Mr. Saccomano disposed of 87 shares of Class A Common Stock at a weighted average price of $2.9677 per share. These shares were automatically sold to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) under the company's 2023 RSU Equity Incentive Plan. Following this transaction, Mr. Saccomano owns 7,419 shares. The filing also notes the existence of RSUs and includes information about shares acquired through an employee stock purchase plan. The transaction was executed through multiple trades with prices ranging from $2.82 to $3.04.